The pharma sees the drug, gefurulimab, as a more convenient, self-administered alternative to the infused medicines it sells ...

AstraZeneca (LSE:AZN) announced promising trial results for gefurulimab, a potential new treatment for generalized myasthenia ...

The company didn’t share specific data for the molecule, gefurulimab, but said it hit all endpoints in the Phase III PREVAIL ...

Results from the Phase III PREVAIL trial (NCT05556096) of gefurulimab demonstrated a statistically significant and clinically ...

"gMG race hots up as AstraZeneca’s star candidate meets Phase III targets" was originally created and published by Clinical ...

AstraZeneca's gefurulimab showed clinical benefits and favorable safety in Phase 3 trial for adults with anti-AChR ...

AstraZeneca said on Thursday its experimental therapy, gefurulimab, met the primary goal and all secondary endpoints in a ...

Gefurulimab is a dual-binding nanobody designed to bind to the C5 protein in the terminal complement cascade and prevent the overactivation of the body’s immune system.

UK pharma major AstraZeneca is preparing to advance gefurulimab as a potential new treatment for generalized myasthenia ...

The phase 3 trial randomized 260 people with anti-acetylcholine receptor antibody-positive gMG to take gefurulimab or placebo. After 26 weeks, people on gefurulimab performed significantly better on a ...

Astrazeneca plc seems on the way to expanding its presence in myasthenia gravis (MG) with positive “high-level” results from ...

(Alliance News) - AstraZeneca PLC on Thursday said its investigational complement C5 inhibitor gefurulimab showed statistically significant results in treating adults with a form of generalised ...